Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 4/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1720309 | 0.83 | MAOB (0.46) | MAOBMAOA | |
| Hydrochloric Acid SCHEMBL16446863 | 0.81 | MAOB (0.48) | MAOBMAOA | |
| SCHEMBL8005872 | 0.80 | MAOB (0.39) | MEN1CYP2C9KMT2AMAOBMAOA | |
| SCHEMBL7991720 | 0.80 | HSD11B1 (0.44) | MEN1CYP2C9KMT2AMAOBMAOA | |
| SCHEMBL8003824 | 0.79 | PIM1 (0.39) | MEN1CYP2C9KMT2AHSD11B1 | |
| SCHEMBL612898 | 0.79 | MAOB (0.43) | MAOBMAOAHSD11B1 | |
| SCHEMBL12920581 | 0.79 | MEN1 (0.63) | MEN1CYP2C9KMT2AMAOBMAOA | |
| SCHEMBL614021 | 0.79 | MEN1 (0.63) | MEN1CYP2C9KMT2A | |
| SCHEMBL8352395 | 0.79 | — | — | |
| SCHEMBL8352354 | 0.79 | AKT1 (0.44) | MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513229-B2 | 4-Azetidinyl-1-phenyl-cyclohexane antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20120040960-A1 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040960-A1 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | MEN1 4312/4885CYP2C9 1738/4885KMT2A 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.